Introduction: Little is known about the biology, molecular profile and hence optimal treatment of African Nigerian breast cancer. The aim of this work, therefore, was to characterize the histology and molecular profile of Nigerian breast cancer. Methods: Breast carcinomas from women at 6 centres of similar tribal origin in Nigeria were reviewed and assembled into tissue microarrays (TMAs), and sections were stained for hormone receptors, i.e. estrogen receptor (ER)α, ERβ1, ERβ progesterone receptor (PR) and androgen receptor, cyclin D, HER2, Ki67 and cytokeratins (CKs), i.e. CK5/6 and CK14 (basal) and CK18 and 19 (luminal). Results: A total of 835 tumours were analysed. The mean age at diagnosis was 48.62 ± 12.41 years. The most common histological subtype was ductal NST (no-special-type) carcinoma (87.3%). Over 90% of the tumours were grade 2 or 3. The predominant molecular phenotype was the non-basal, triple-negative type (47.65%) followed by the HER2-positive group (19.6%). The percentage of ER-, PR- and HER2-positive tumours was 22.4, 18.9 and 18.8%, respectively. Conclusion: Nigerian breast cancer predominantly has a high-grade, triple-negative profile. It occurs at a younger age and bears similarities at the molecular level to pre-menopausal breast cancer in white women, with remarkably lower levels of ERβ expression. The early presentation and histological and molecular phenotype may explain the poor prognosis, and tailoring treatment strategies to target this unique profile are required.

Keywords:
Breast cancer, Tissue microarray, Estrogen receptor expression
1.
Hausauer AK, Keegan TH, Chang ET, Clarke CA: Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the USA: changes by tumor subtype. Breast Cancer Res 2007;9:R90.
2.
Li CI, Malone KE, Daling JR: Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 2003;163:49-56.
3.
Li CI, Malone KE, Daling JR: Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 2002;11:601-607.
4.
Newman LA, Bunner S, Carolin K, et al: Ethnicity related differences in the survival of young breast carcinoma patients. Cancer 2002;95:21-27.
5.
Brown LA, Hoog J, Chin SF, et al: ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008;40:806-807.
6.
Nggada HA, Yawe KD, Abdulazeez J, Khalil MA: Breast cancer burden in Maiduguri, northeastern Nigeria. Breast J 2008;14:284-286.
7.
Bird PA, Hill AG, Houssami N: Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol 2008;15:1983-1988.
8.
Adebamowo CA, Famooto A, Ogundiran TO, et al: Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat 2008;110:183-188.
9.
NHS Cancer Screening Programmes, Royal College of Pathologists: Pathology Reporting of Breast Disease 2005.
10.
Shaaban AM, Green AR, Karthik S, et al: Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008;14:5228-5235.
11.
Pinder SE, Brown JP, Gillett C, et al: The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. J Clin Pathol 2013;66:169-177.
12.
Shaaban AM, Ball GR, Brannan RA, et al: A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat 2012;133:949-958.
13.
Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 2000;406:747-752.
14.
Callagy G, Cattaneo E, Daigo Y, et al: Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003;12:27-34.
15.
Abd El-Rehim DM, Ball G, Pinder SE, et al: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116:340-350.
16.
Abd El-Rehim DM, Pinder SE, Paish CE, et al: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-671.
17.
Gnant M, Thomssen C, Harbeck N: St. Gallen/Vienna 2015: a brief summary of the consensus discussion. Breast Care (Basel) 2015;10:124-130.
18.
Agboola AJ, Musa AA, Wanangwa N, et al: Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat 2012;135:555-569.
19.
McCormack VA, Joffe M, van den Berg E, et al: Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series. Breast Cancer Res 2013;15:R84.
20.
Ohene-Yeboah M, Adjei E: Breast cancer in Kumasi, Ghana. Ghana Med J 2012;46:8-13.
21.
Titiloye N, Omoniyi-Esan G, Adisa A, et al: Breast cancer in a Nigerian cohort: histopathology, immunohistochemical profile and survival. Postgrad Med J Ghana 2013;2:83-86.
22.
Stark A, Kleer CG, Martin I, et al: African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer 2010;116:4926-4932.
23.
Awadelkarim KD, Arizzi C, Elamin EO, et al: Tissue microarray (TMA) versus whole section immunohistochemistry in the assessment of ER/PR and Her-2/neu status in a breast cancer series from Sudan. Breast J 2013;19:446-447.
24.
Ly M, Antoine M, Dembele AK, et al: High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncology 2012;83:257-263.
25.
Rambau PF, Chalya PL, Manyama MM, Jackson KJ: Pathological features of breast cancer seen in northwestern Tanzania: a nine years retrospective study. BMC Res Notes 2011;4:214.
26.
Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL: Early onset of breast cancer in a group of British black women. Br J Cancer 2008;98:277-281.
27.
Ingleby JD: Early onset of breast cancer in Black British women: how reliable are the findings? Br J Cancer 2008;99:986-987.
28.
National Cancer Intelligence Unit: Second All Breast Cancer Report. http://www.cancerscreening.nhs.uk/breastscreen/second-all-breast-cancer-report.pdf (2011).
29.
Gukas ID, Jennings BA, Mandong BM, et al: A comparison of the pattern of occurrence of breast cancer in Nigerian and British women. Breast 2006;15:90-95.
30.
Cancer Research UK: Breast cancer incidence statistics, 2013.
31.
McCormack VA, Perry N, Vinnicombe SJ, Silva Idos S: Ethnic variations in mammographic density: a British multiethnic longitudinal study. Am J Epidemiol 2008;168:412-421.
32.
Phipps AI, Buist DS, Malone KE, et al: Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 2011;22:399-405.
33.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007;109:1721-1728.
34.
Aapro M, Wildiers H: Triple-negative breast cancer in the older population. Ann Oncol 2012;23(suppl 6):vi52-vi55.
35.
Agboola AO, Banjo AA, Anunobi CC, et al: Cell proliferation (KI-67) expression is associated with poorer prognosis in Nigerian compared to British breast cancer women. ISRN Oncol 2013:675051.
36.
Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO: E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005;46:685-693.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.